AACR-KCA 2024 (American Association of Cancer Research-Korea Cancer Association)
Zolbetuximab plus chemotherapy as first-line treatment in patients with claudin 18.2 (CLDN18.2)+, HER2?, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Korean population subgroup―combined efficacy and safety analysis from SPOTLIGHT and GLOW
구분
국외
국가
대한민국
컨퍼런스명
AACR-KCA 2024 (American Association of Cancer Research-Korea Cancer Association)
발표 제목
Zolbetuximab plus chemotherapy as first-line treatment in patients with claudin 18.2 (CLDN18.2)+, HER2?, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: Korean population subgroup―combined efficacy and safety analysis from SPOTLIGHT and GLOW